Trump signs executive order to reschedule marijuana, expand access to CBD products

President Trump signed an executive order directing the federal government to move marijuana from Schedule I to Schedule III and to work with Congress to expand access to hemp-derived CBD, while leaving recreational use federally illegal. The order instructs the attorney general to expedite rescheduling—HHS and FDA have recommended the change and DOJ issued a proposed rule in May 2024 that drew ~43,000 comments—and industry lawyers say rescheduling could relieve crippling tax burdens and broaden research and financial access. Despite the policy shift's potential long-term benefits for cannabis firms and markets, US multi-state operators and cannabis ETFs fell sharply on the announcement (US operators posted double-digit declines; ETFs dropped about 12%), with Canadian licensed producers outperforming U.S. peers.

Analysis

Market Structure: Rescheduling to Schedule III (if finalized) benefits federally-aligned players (banks, payment processors, pharmas, greentech licensors) and Canadian LPs (CGC, CRON, ACB, SNDL) that can access capital and US distribution via exports or partnerships. Short-term losers are US MSOs and cannabis ETFs (MSOS fell ~12% on the news) because headline uncertainty and profit-taking reduce liquidity; tax relief (potential 280E mitigation) could lift after-tax margins by an estimated 5–15 percentage points over 12–24 months for compliant operators.

Risk Assessment: Tail risks include judicial stays or Congressional pushback, rapid consolidation by Big Tobacco/Big Pharma that compresses producer margins, and banking rule delays; any of these could wipe out >50% of expected equity upside. Immediate (days) = elevated volatility; short-term (3–6 months) = Reuters/DOJ rulemaking and IRS 280E guidance windows; long-term (12–36 months) = structural winners emerge as capital, research, and M&A normalize.

Trade Implications: Tactical plays: favor Canadian LPs and cannabis-adjacent financials while hedging US MSO exposure; use 12–18 month LEAP calls 20–30% OTM on CGC/CRON and buy 3–6 month put spreads on MSOS for downside protection. Entry on 10–20% pullbacks or on DOJ publication (expected within 90–180 days); target 30–60% upside on successful 280E/ banking clarifications, stop-loss at 20%.

Contrarian Angles: The market underestimates timing friction—executive order accelerates process but real cashflow benefits lag 6–18 months, so immediate selloffs could be oversold buying opportunities. Unintended consequence: Schedule III could catalyze pharmaceutical isolates, commoditizing high-margin branded flower and pressuring cultivators; treat plant-touching equities as binary outcome bets, not linear reflation trades.

Key Decisions for Investors

• Establish a 2–3% long position in CGC and a 1.5–2% long position in CRON via 12–18 month LEAP call spreads (≈25% OTM buy, financed by selling 50% premium nearer-term calls) if either stock drops >10% or upon DOJ final rule within 90 days; target +30–60% in 12 months, stop-loss 20%.
• Hedge/short US MSO beta: allocate 1.5–2% notional to buy MSOS 3–6 month put spreads (buy 15% OTM put, sell 30% OTM put) to capture further ETF downside and volatility; unwind if MSOS rallies >20% or DOJ/IRS issue strongly favorable guidance to US MSOs.
• Pair trade: Go long CGC+CRON (equal-weighted, total 3–4% portfolio) and short a basket of large US MSOs (net short exposure 2% via swaps or ETF) targeting 25–40% relative outperformance in 6–12 months; cut the pair if relative underperformance exceeds 15% over any 30-day window.